skip to content
Primary navigation

Rebyota™

Drug - Rebyota™ (fecal microbiota, live - jslm) [Ferring Pharmaceuticals Inc.]

January 2025

Therapeutic area - Antibiotics, GI

Approval criteria

  • Patient ≥ 18 years of age; AND
  • Patient has a confirmed diagnosis of recurrent Clostridioides difficile infection (CDI) with a total of ≥ 3 episodes of CDI within 12 months; AND
  • Antibiotic treatment for recurrent CDI must be completed 24 to 72 hours prior to initiation of Rebyota therapy; AND
  • Rebyota is prescribed by, or in consultation with, an infectious disease or gastrointestinal specialist

Quantity limits

  • 150 mL as a single dose

Billing for Rebyota

Rebyota must be billed as a medical claim.

Background

Rebyota is not indicated for treatment of CDI.

Questions

Provider Call Center (844) 575-7887

back to top